Literature DB >> 11227772

MRI in the diagnosis and treatment of suspected malignant spinal cord compression.

D J Husband1, K A Grant, C S Romaniuk.   

Abstract

It remains unclear whether MRI is essential in all patients with suspected malignant spinal cord compression (MSCC), or whether some patients can be treated on the basis of plain radiographic findings and neurological examination. A prospective study was carried out of 280 consecutive patients with suspected MSCC, and the results of neurological examination plus plain radiographs were compared with MRI. 201 patients had MSCC (186 extradural, 5 intradural extramedullary and 10 intramedullary) and 11 patients had thecal sac compression without evidence of spinal cord compression. 25% of patients with MSCC had two or more levels of compression, 69% of these involving more than one region of the spine. A paraspinal mass was noted at the site of extradural spinal cord compression in 28%, and only one-third of these were detected on plain radiography. Focal radiographic changes and consistent neurology were present in 91 (33%) patients who had not had previous radiotherapy. MRI confirmed the presence of MSCC in 89/91 patients (specificity and positive predictive value of radiographic/clinical findings 98%) and the level of disease in all. MRI led to a change in the radiotherapy plan in 53% of patients (21% major change). The sensory level when present was four or more segments below the MRI level in 25/121 (21%) patients, and two or more levels above in 8/121 (7%) patients. Although focal radiographic abnormalities with consistent neurological findings, when present, accurately predicted the presence and level of MSCC, whole spine MRI is indicated in most patients with suspected MSCC because the additional information may alter the management plan. Treatment may be appropriately initiated on the basis of focal radiographic changes and consistent neurology if MRI is contraindicated or delayed, and in patients with a poor prognosis. In patients in whom there are no focal radiographic abnormalities and consistent neurological findings, urgent MRI is mandatory before radiotherapy is commenced.

Entities:  

Mesh:

Year:  2001        PMID: 11227772     DOI: 10.1259/bjr.74.877.740015

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  8 in total

Review 1.  [Compression syndromes].

Authors:  J Wierecky; C Bokemeyer
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 2.  Medical imaging in the diagnosis and management of cancer pain.

Authors:  Carlos Cuevas; Dean Shibata
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 3.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

4.  Rapid magnetic resonance imaging for diagnosing cancer-related low back pain.

Authors:  William Hollingworth; Darryl T Gray; Brook I Martin; Sean D Sullivan; Richard A Deyo; Jeffrey G Jarvik
Journal:  J Gen Intern Med       Date:  2003-04       Impact factor: 5.128

5.  Diffusion-weighted MR imaging (DWI) in the evaluation of epidural spinal lesions.

Authors:  Christina Plank; Anke Koller; Christina Mueller-Mang; Roland Bammer; Majda M Thurnher
Journal:  Neuroradiology       Date:  2007-10-19       Impact factor: 2.804

6.  A case of indirect cauda equina syndrome from metastatic prostate cancer.

Authors:  Shilo Lefresne; Alysa Fairchild; Aalo Bistritz; Peter Venner; Don Yee
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

7.  Epidural Spinal Cord Compression.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Treat Options Neurol       Date:  2004-07       Impact factor: 3.598

8.  Malignant spinal cord compression: a retrospective audit of clinical practice at a UK regional cancer centre.

Authors:  A McLinton; C Hutchison
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.